Table 1 Clinical trials with mRNA vaccines against cancer
Cancer tpye | NCT number | Drug administration | Phase | Status |
|---|---|---|---|---|
Non-small Cell Lung Cancer | NCT03164772 | BI 1361849 (CV9202) + Durvalumab+/−Tremelimumab | I/II | Recruiting |
NCT03908671 | Personalized mRNA vaccine encoding neoantigen | – | Not yet recruiting | |
NCT02688686 | Suppressor of cytokine signaling (SOCS) 1, MUC1 and Survivin mRNA-loaded DC + cytokine-induced killer | I/II | Unknown | |
Ovarian Cancer | NCT04163094 | W_ova1 + carboplatin/paclitaxel | I | Recruiting |
NCT01334047 | DC-006 vaccine | I/II | Terminated | |
NCT01456065 | DCs loaded with TERT-mRNA and Survivin-peptide | I | Unknown | |
Melanoma | NCT00204607 | mRNA+GM-CSF | I/II | Completed |
NCT00978913 | DCs transfected with hTERT, survivin and p53 | I | Completed | |
NCT00940004 | Dendritic cells electroporated with mRNA encoding gp100 and tyrosinase | I/II | Completed | |
NCT01066390 | TriMix-DC | I | Completed | |
NCT02285413 | DCs loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase+/−cisplatinum | II | Completed | |
NCT00204516 | mRNA coding for melanoma associated antigens+GM-CSF | I/II | Completed | |
NCT01278940 | mRNA-transfected DCs + IL-2 | I/II | Completed | |
NCT01530698 | autologous dendritic cell vaccine by mRNA Electroporation | I/II | Completed | |
NCT00243529 | Autologous dendritic cell vaccine | I/II | Completed | |
NCT03897881 | mRNA-4157 + pembrolizumab | II | Recruiting | |
NCT01456104 | Autologous Langerhans-type dendritic cells electroporated with mRNA encoding a tumor-associated antigen | I | Active, not recruiting | |
NCT02410733 | Lipo-MERIT | I | Active, not recruiting | |
NCT00961844 | Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA+ex vivo T cell expansion and reinfusion+Temozolomide | I/II | Terminated | |
NCT03480152 | (NCI)-4650, a mRNA-based, personalized cancer vaccine | I | Terminated | |
NCT00929019 | Autologous dendritic cells electroporated with mRNA | I/II | Terminated | |
Brain Cance (mainly glioblastoma) | NCT00846456 | Tumor stem cell derived mRNA- transfected dendritic cells | I/II | Completed |
NCT00626483 | CMV pp65-LAMP mRNA-loaded DC + GM-CSF | I | Completed | |
NCT03548571 | DCs transfected with mRNA encoding survivin and hTERT+temozolomide | II/III | Completed | |
NCT03927222 | Human CMV pp65-LAMP mRNA-pulsed autologous DCs + temozolomide+tetanus-diphtheria toxoid+GM-CSF | II | Recruiting | |
NCT02649582 | Autologous WT1 mRNA-loaded DC + temozolomide | I/II | Recruiting | |
NCT03688178 | Human CMV pp65-LAMP mRNA-pulsed autologous DCs + temozolomide+varlilumab+tetanus-diphtheria (Td) toxoid+111In-labeled DCs + unpulsed DCs | II | Recruiting | |
NCT02465268 | pp65-shLAMP mRNA DCs + GM-CSF | II | Recruiting | |
NCT02808416 | Personalized cellular vaccine | I | Active, not recruiting | |
NCT02709616 | mRNA-TAA pulsed autologous DC | I | Active, not recruiting | |
NCT00639639 | CMV-ALT+CMV pp65-LAMP mRNA-loaded DC (CMV-DC) | I | Active, not recruiting | |
NCT02366728 | Human CMV pp65-LAMP mRNA-pulsed autologous DCs | II | Active, not recruiting | |
NCT01291420 | WT1 mRNA-electroporated autologous dendritic cell | I/II | Unknown | |
NCT00890032 | BTSC mRNA-loaded DCs | I | Unknown | |
Prostate Cancer | NCT01278914 | mRNA-transfected dendritic cells | I/II | Completed |
NCT01446731 | DCs transfected with PSA, PAP, survivin and hTERT mRNA+docetaxel | II | Completed | |
NCT02692976 | DC loaded with protamine/mRNA encoding keyhole limpet hemocyanin (KLH) + DC loading with MHC I binding peptides, NY-ESO-1 and MUC1 PepTivator® | II | Completed | |
NCT01197625 | Dendritic cell vaccine | I/II | Active, not recruiting | |
NCT01153113 | Human telomerase reverse transcriptase mRNA (hTERT mRNA) transfected dendritic cell | I/II | Withdrawn | |
NCT02140138 | CV9104 | II | Terminated | |
NCT02452307 | Peptide vaccine+montanide ISA-51+/−GM-CSF+/−imiquimod+/−mRNA/protamin | I/II | Unknown | |
Blood System Cancer (leukemia mainly) | NCT00834002 | Wilms Tumor Gene (WT1) mRNA-transfected autologous dendritic cell | I | Completed |
NCT01734304 | DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65 | I/II | Completed | |
NCT00510133 | GRNVAC1 (mRNA encoding human telomerase reverse transcriptase (hTERT) and a portion of the lysosome-associated membrane protein LAMP-1 (LAMP)) | II | Completed | |
NCT02528682 | MiHA mRNA-loaded PD-L-silenced DC | I/II | Completed | |
NCT01686334 | Autologous WT1 mRNA-electroporated DCs | II | Recruiting | |
NCT01995708 | CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells (LCs) | I | Active, not recruiting | |
NCT03083054 | Autologous dendritic cells electroporated with WT1 mRNA | I/II | Active, not recruiting | |
NCT00514189 | Autologous dendritic cells | I | Terminated | |
NCT00965224 | mRNA coding for Wilms’ tumor antigen WT1 | II | Unknown | |
Digestive System Cancer | NCT00228189 | CEA mRNA-loaded DCs | I/II | Completed |
NCT03468244 | Personalized mRNA vaccine encoding neoantigen | – | Recruiting | |
NCT02693236 | Adenovirus-transfected autologous DCs + CIK cells | I/II | Unknown |